Medtronic PLC (MDT) is a leading medical devices business with stocks listed in the US. It opened the day at US$78.9 after a previous close of US$79. During the day the price has varied from a low of USD78.4 to a high of USD79.05. The latest price was USD78.86 (25 minute delay). Medtronic is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
Medtronic's shares were split on a 2:1 basis on 27 September 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
| Open | US$78.9 |
|---|---|
| High | US$79.05 |
| Low | US$78.4 |
| Close | US$78.86 |
| Previous close | US$79 |
| Change | US$-0.14 |
| Change % | -0.1772% |
| Volume | 3,033,048 |
| 52-week range | US$68.84 - US$90.5279 |
|---|---|
| 50-day moving average | US$74.9124 |
| 200-day moving average | US$81.9821 |
| Target price | US$90.15 |
| PE ratio | 25.6396 |
| Dividend yield | US$2.74 (3.49%) |
| Earnings per share (TTM) | US$3.08 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $78.86
| 1 week (2023-11-21) | 0.31% |
|---|---|
| 1 month (2023-10-27) | 13.58% |
| 3 months (2023-08-28) | -3.11% |
| 6 months (2023-05-26) | -3.19% |
| 1 year (2022-11-28) | 3.59% |
|---|---|
| 2 years (2021-11-26) | -28.99% |
| 3 years (2020-11-27) | -31.18% |
| 5 years (2018-11-28) | -17.31% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Medtronic shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0399. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$8.7 billion (£6.8 billion).
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.
Over the last 12 months, Medtronic's shares have ranged in value from as little as US$68.84 up to US$90.5279. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.722. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
| Revenue TTM | US$32 billion |
|---|---|
| Operating margin TTM | 20.77% |
| Gross profit TTM | US$21.7 billion |
| Return on assets TTM | 4.23% |
| Return on equity TTM | 7.96% |
| Profit margin | 12.84% |
| Book value | 38.687 |
| Market capitalisation | US$105.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 41.39% of net profits
Recently Medtronic has paid out, on average, around 41.39% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.49% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.74 per share.
While Medtronic's payout ratio might seem fairly standard, it's worth remembering that Medtronic may be investing much of the rest of its net profits in future growth.
Medtronic's most recent dividend payout was on 13 October 2023. The latest dividend was paid out to all shareholders who bought their shares by 21 September 2023 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 01/01/2019) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Medtronic PLC was last rated for ESG on: 2019-01-01.
| Total ESG score | 26.86 |
|---|---|
| Total ESG percentile | 40.62 |
| Environmental score | 4.07 |
| Environmental score percentile | 5 |
| Social score | 15.28 |
| Social score percentile | 5 |
| Governance score | 9 |
| Governance score percentile | 5 |
| Level of controversy | 3 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
